Dis 2012, 54:1785792. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA: Clinical practice guideline for the usage of antimicrobial agents in neutropenic individuals with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011, 52:e56 93. Drusano GL, DeJongh C, Newman K, Joshi J, Wharton R, Moody MR: Moxalactam and Piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer individuals. Infection 1985, 13:206. Drusano GL, Forrest A, Plaisance KI, Wade JC: A potential evaluation of optimal sampling theory in the determination with the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther 1989, 45:63541. Levey AS, Coresh J, Bolton K, Culleton B, Schiro K, Alp T: Recommendations for chronic kidney disease: evaluation, classification and stratification.Papain Am J Kidney Dis 2002, 39(Suppl 1):S1 266. Infante-Rivard C, Esnaola S, Villeneuve JP: Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987, 7:66064. Ritschel WA, Kearns JL: Handbook of Standard Pharmacokinetics. 4th edition. American Pharmacists Association: Washington; 1992. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH: Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and four.5G Q6h. Chemother 2002, 48:593. Strayer AH, Gilbert DH, Pivarnik P, Medeiros AA, Zinner SH, Dudley MN: Pharmacodynamics of piperacillin alone and in mixture with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.Hemocyanin Antimicrob Agents Chemother 1994, 38:2351356.PMID:23557924 Shea KM, Cheatham C, Matthew F, Wack M, Smith DW, Sowinski KM, Kays MB: Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered through prolonged infusion in hospitalised patients. Internat J Antimicrob Agents 2009, 34:42933. Auclair B, Ducharme MP: Piperacillin and tazobactam exhibit linear pharmacokinetics immediately after a number of normal clinical doses. Antimicrob Agents Chemother 1999, 43:1465468. Benet LZ, Kroetz DL, Sheiner LB: Pharmacokinetics, Goodman Gilman’s the pharmacological basis of therapeutics, Volume 1.1. 2nd edition. Philadelphia: McGraw Hill; 2011:39. Langgartner J, Lehn J, Gl k T, Herzig H, Kees F: Comparison in the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemother 2007, 53:37077.doi:10.1186/2050-6511-14-59 Cite this short article as: varez et al.: Pharmacokinetics of piperacillin/ tazobactam in cancer patients with hematological malignancies and febrile neutropenia following chemotherapy. BMC Pharmacology and Toxicology 2013 14:59.Submit your subsequent manuscript to BioMed Central and take complete advantage of:Convenient on-line submission Thorough peer critique No space constraints or colour figure charges Quick publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Research that is freely out there for redistributionSubmit your manuscript at www.biomedcentral/submit
Naugler et al. BMC Public Health 2013, 13:316 http://www.biomedcentral/1471-2458/13/RESEARCH ARTICLEOpen AccessAssociation of vitamin D status with socio-demographic aspects in Calgary, Alberta: an ecological study using Census Canada dataChristopher Naugler1,2,3,4*, Jianguo Zhang5, Dan Henne3, Paul Woods2 and Brenda R HemmelgarnAbstractBackground: Low 25-hydroxyvitamin D levels are.
